Navigation Links
SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Date:9/12/2007

ISELIN, N.J., Sept. 12 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD.OB), today announced that it will host a symposium entitled "Post-Operative Adhesions in Cardiac Surgery: Challenges and Solutions" for surgeons attending next week's European Association for Cardio- Thoracic Surgery Annual Meeting in Geneva, Switzerland. The symposium will be chaired by Professor Stephen Westaby of the John Radcliffe Hospital in Oxford, United Kingdom and will include presentations by principal investigators who participated in US and European clinical trials for REPEL-CV(R) Adhesion Barrier, the company's novel bioresorbable film intended to reduce the formation of adhesions (scar tissue) in cardiac surgical procedures. Professor Westaby stated, "It is important to inform our surgeon colleagues that, with REPEL-CV, we now appear to a have way of reducing patient risks associated with the presence of adhesions during cardiac reoperations."

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Symposium will include venture capital "coaching"
2. Fusion 2006 symposium focuses on making IT work for businesses
3. Early Stage Symposium session will help emerging companies prepare for investors
4. Food microbiology symposium will mark 25 years
5. High interest forces delay in food safety symposium
6. Milwaukee to host inaugural Great Lakes Agro-Security Symposium
7. Fusion 2005 symposium aims to bring CIOs to the boardroom
8. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
9. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
10. Symposium examines the effect of race on genetics and disease
11. Belmont Report Commission reuniting for Medical College of Wisconsin Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Proove Biosciences, Inc ., ... the launch of the Proove Health Foundation . The Foundation is a ... the use of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As ...
(Date:4/29/2016)... April 29, 2016 According ... Market Research "Separation Systems for Commercial Biotechnology Market ... and Forecast 2015 - 2023", the separation systems ... 10,665.5 Mn in 2014 and is projected to ... to 2023 to reach US$ 19,227.8 Mn in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell ... the development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease. ... Dr. Jeanne Loring at The Scripps Research Institute in San Diego, CA. ...
(Date:4/29/2016)... -- Elekta is pleased to announce that ... treatment planning software, is available for clinical release. Real-world ... version 5.11 provides significant performance speed enhancements over prior ... four times faster than in previous versions of ... Monte Carlo algorithm, users can ...
Breaking Biology Technology:
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
(Date:3/2/2016)... http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the addition ... Service Market 2016-2020" report to their ... Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ...
Breaking Biology News(10 mins):